Novel pH-responsive dextrin nanogels for doxorubicin delivery to cancer cells with reduced cytotoxicity to cardiomyocytes and stem cells.
The aim of this study was to develop pH-responsive dextrin nanogels (DNGs) capable of triggered intracellular DOX release at the lower pH of cancer cells. DNGs were prepared by an emulsion cross-linking method using glyoxal as cross-linker to create an acid-labile bond. A higher molecular weight of dextrin with increasing mole ratio of dextrin to glyoxal decreased the average diameter of DNGs. DNGs showed slightly negative surface charge and pH-responsive behavior. The in vitro drug release was slow at pH 7.4 and increased with decreasing pH (pH 5>6.8). The cytotoxicity of DOX-loaded DNGs in mesenchymal stem cells and cardiomyocytes was lower than that of free DOX. Moreover, DOX-loaded DNGs were efficiently internalized by tumor cells with rapid release of DOX into the nucleus. Thus, DOX-loaded DNGs were successful for intracellular targeted anti-tumor drug delivery and reducing side-effects to non-tumor cells such as cardiomyocytes and stem cells.
['Manchun|Somkamol|S|', 'Cheewatanakornkool|Kamonrak|K|', 'Dass|Crispin R|CR|', 'Sriamornsak|Pornsak|P|']
D000818:Animals D045744:Cell Line, Tumor D002470:Cell Survival D003912:Dextrins D004317:Doxorubicin D016503:Drug Delivery Systems D006863:Hydrogen-Ion Concentration D051379:Mice D032383:Myocytes, Cardiac D000080385:Nanogels D011092:Polyethylene Glycols D011094:Polyethyleneimine D051381:Rats D013234:Stem Cells
pH-responsive Dextrin Nanogels Doxorubicin Cancer